Skip to main content
. 2016 Oct 15;7(50):82493–82503. doi: 10.18632/oncotarget.12696

Figure 5. Anti-FIRΔexon2 or anti-FIR antibodies were detected in the sera of various cancer patients.

Figure 5

Purified proteins were prepared by Nus-tag FIR or -FIRΔexon2 as antigens. Alpha counts against FIR or FIRΔexon2 proteins were indicated in healthy subjects (n = 92), breast cancer (n = 82), pancreatic cancer (n = 80). bile duct cancer (n = 77), gall bladder stones (n = 48), pancreatic neuroendocrine tumor (n = 24), esophageal cancer (n = 91), gastric cancer (n = 90), and colorectal cancer (n = 89) patients.